CN

CN
WuXi AppTec Research Service Division

The WuXi AppTec Research Service Division (RSD) supports clients in the discovery and development of future therapeutics. Through comprehensive discovery and technology platforms, peer-recognized scientific leadership and expertise in oncology, immunology, infectious disease, neurosciences, fibrosis, cardiovascular and metabolic disease, RSD works collaboratively to rapidly advance programs from target through to preclinical selection and beyond.

RSD’s discovery platform encompasses biology, chemistry, structural biology, biophysics and ADME/PK, in addition to the capabilities of newly acquired HD Biosciences (HDB), and is trusted by over 3,000 international clients, ranging from pharma and biotech to academia and non-profit institutions.

This integration of capabilities allows a collaborative environment, enabling enhanced efficiency and productivity. WuXi AppTec RSD strives to continually develop and enhance its scientific capabilities and technology to maintain its industry leading position. We aim to provide outstanding services to our existing partners and to the broader discovery community!

Over 5,000 chemists, 1,000 biologists and 400 analytical scientists
Laboratories and sites across US, EU and China
Over 7,000 chemical reactions everyday
AAALAC-accredited facility & GCP/CAP compliant laboratories
7,000+
Total Global Employees
140,000+
Area of Laboratory (sq.m.)
3,000+
Global Customers
14
Global Site and Office
RSD Integrated Platform
R&D
Biological Science
Chemistry
Target-to-hit
  • Target validation, CRISPR
  • Protein production
  • HTS, FBDD
  • X-ray crystallography
  • Biophysical analytics
  • CADD
  • Reference compounds
  • Arrays, libraries, DELs
  • Unique scaffolds, building blocks
  • DNA Encoded Libraries
  • Customized screening decks
Hit-to-lead
  • In vitro efficacy & MoA
  • In vivo efficacy
  • PK/PD analysis
  • SAR generation
  • Molecule design
  • Building blocks
Lead optimization
  • In vitro SAR support
  • Selectivity panel
  • Cell panel
  • In vivo target engagement
  • In vivo pharmacology
  • Optimization of hits and leads
  • Data interpretation
  • Candidate selection
Pre-clinical
  • hERG, other safety profiling services
  • Ligand binding
  • Receptor profiling
  • Additional in vitro and in vivo characterization
  • Scale up of candidates for preclinical studies
  • Synthetic optimization of candidates
  • Metabolic and impurity identification synthesis
Clinical l - lll
  • PDX
  • Tumor TILs
  • Biomarkers
  • CAP-certified FACS, pathology, molecular testing
Partnering with RSD
  • Track record of delivery, leadership and scientific excellence
  • A comprehensive and integrated portfolio of discovery services
  • >7,000 scientists across chemistry, analytical and biology
  • Cost-effective, scalable solutions delivering quality data
  • Global footprint with operations in North America, Asia and Europe
  • Established IP protection policies and procedures. Seamless pathway from our discovery platforms to our development platforms
Delivering our partners preclinical discoveries through world class capabilities,
directed by teams with a reputation for collaboration and scientific excellence.
WuXi AppTec
Research Service Division
Leadership and Excellence in Contract Research
RSD enables anyone or any company to discover and develop new drugs and products with a benefit to patients. RSD services deliver extraordinary performance and an unwavering focus on customer satisfaction.
Comprehensive R&D Enabling Capability